Sakar Healthcare

Sakar Healthcare FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sakar Healthcare (SAKAR.NS) as of Nov 6, 2026 is 36.15 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 10.00 % — a change of 261.62% (higher).

FCF Conversion

36.15 %

YoY

261.62%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sakar Healthcare is 2026 36.15 % . FCF Conversion Rate (FCF/EBITDA) of Sakar Healthcare was 2025 10.00 % . It decreases by 261.62% higher compared to the previous year.

The Sakar Healthcare FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
-82.79 INR
Jan 1, 2020
-36.81 INR
Jan 1, 2021
-196.29 INR
Jan 1, 2022
-405.66 INR
Jan 1, 2023
-367.45 INR
Jan 1, 2024
-300.69 INR
Jan 1, 2025
10.00 INR
Jan 1, 2026
36.15 INR
The Sakar Healthcare FCF Conversion history
YEARFCF ConversionYoY
36.15 %+261.62%
10.00 %-103.32%
-300.69 %-18.17%
-367.45 %-9.42%
-405.66 %+106.66%
-196.29 %+433.31%
-36.81 %-55.54%
-82.79 %-10.91%
-92.93 %+2.39 M%
-0.00-259.87%
0.00-100.00%
190.99 %-42.76%
333.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sakar Healthcare Stock analysis

What does Sakar Healthcare do? Sakar Healthcare Ltd. manufactures pharmaceutical products including liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectables (SVP) in ampoules and vials, lyophilized injections, and oral solid dosages. The company operates as a contract development and manufacturing organization (CDMO) providing these products under brand names such as Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid, and Lyophilised Injections (In Vials). Sakar Healthcare serves markets in 14 countries including Uganda, Kenya, Yemen, Ethiopia, Congo, Zimbabwe, Nigeria, Malawi, Philippines, Peru, Vietnam, and Cote D’Ivoire with approximately 321 product registrations. The company generates revenue through the sale of these pharmaceutical products to healthcare providers and distributors in these regions. The firm’s manufacturing unit is accredited by regulatory authorities in 14 countries, which enables it to produce and distribute products across these markets. Sakar Healthcare’s product portfolio includes liquid injectables (SVP) in ampoules and vials, dry powder injections, and oral solid dosages, which are sold to healthcare facilities and pharmacies. The company’s contracts with clients in the pharmaceutical sector involve developing and manufacturing products according to their specifications, with the firm’s focus on cephalosporin-based medications and liquid formulations. Sakar Healthcare Ltd. focuses on providing contract manufacturing services for pharmaceutical products, with a strong emphasis on cephalosporin formulations and liquid-based medications. The company’s products are registered in 321 product registrations across various countries, supporting its operations in 14 regulatory markets. Revenue is derived from the production and sale of these registered products to healthcare providers and distributors in the regions where it holds regulatory accreditation. Sakar Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sakar Healthcare stock

FCF Conversion Rate (FCF/EBITDA) of Sakar Healthcare is 36.15 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Sakar Healthcare changed from 10.00 % to 36.15 %, representing a 261.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sakar Healthcare since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sakar Healthcare with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Sakar Healthcare

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Sakar Healthcare